All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2019-05-31T08:52:01.000Z

Addition of survival data on gilteritinib labeling approved by FDA

May 31, 2019
Share:

Bookmark this article

The US Food and Drug Administration has approved the addition of overall survival (OS) data in the labeling for gilteritinib indicated for patients with relapsed or refractory acute myeloid leukemia (R/R AML) with FLT3 mutation.

The ADMIRAL trial (NCT 02421939) was the basis of approval, and enrolled 371 adult patients with R/R AML, and either a FLT3 ITD, D835 or I836 mutation (identified through the LeukoStrat® CDx FLT3 Mutation Assay).

During the study patients randomly (2:1) received gilteritinib 120 mg once daily (n = 247), over 28-day cycles, or salvage chemotherapy (n = 124), which included either intensive cytotoxic chemotherapy, or a low-intensity regimen.

OS was measured from randomization until death by any cause. The median OS was 9.3 months for patients in the gilteritinib cohort and 5.6 months for patients in the chemotherapy cohort. Results were consistent in the intensive chemotherapy arm and the low-intensity chemotherapy arm.

Adverse reactions occurring in at least 20% of patients who received gilteritinib were transaminase, myalgia/arthralgia, fatigue/malaise, fever, mucositis, edema, rash, noninfectious diarrhea, dyspnea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, and renal impairment.

The recommended dose of gilteritinib is 120 mg orally once daily. Full prescribing information can be found here, and contains a Boxed Warning alerting health care professionals and patients about the risk of differentiation syndrome, which may be life-threatening or fatal if not treated.

  1. FDA approves addition of survival data to gilteritinib label for refractory AML with a FLT3 mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-addition-survival-data-gilteritinib-label-refractory-aml-flt3-mutation [accessed 31.05.2019]

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 80 days left ...

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox